

APAC Cancer Immunotherapy Market - Industry Trends and Forecast to 2032

Market Report | 2023-12-01 | 321 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

The Asia-Pacific cancer immunotherapy market is expected to reach USD 28,527.61 million by 2031 from USD 9,669.65 million in 2023, growing at a CAGR of 15.4% during the forecast period of 2024 to 2031.

Market Segmentation

Asia-Pacific Cancer Immunotherapy Market, By Product Type (Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators, and Oncolytic Virus), Application (Lung Cancer, Breast Cancer, Melanoma, Myeloma, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Stomach Cancer, Colorectal Cancer, Head & Neck Cancer, and Others), End User (Hospitals, Oncology Clinics, Homecare, and Others), Form (Intravenous (IV), Intramuscular, and Oral), Distribution Channel (Direct Tenders, Retail Sales, and Pharmacies), Country (China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Philippines, Malaysia, New Zealand, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2031

Overview of Asia-Pacific Cancer Immunotherapy Market Dynamics

Driver

- Rising prevalence of cancer incidences

Restraint

- Increasing occurrence of immune-related adverse events

Opportunity

- Growing trend towards combination therapies

Market Players

Some of the major market players operating in the Asia-Pacific cancer immunotherapy market are listed below:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Janssen Pharmaceutical
- AstraZeneca
- Gilead Sciences, Inc.
- Eli Lilly and Company
- Amgen Inc.
- Novartis AG
- GSK
- Pfizer Inc.
- Incyte

Table of Contents:

TABLE OF CONTENTS

1	INTRODUCTION	83
1.1	OBJECTIVES OF THE STUDY	83
1.2	MARKET DEFINITION	83
1.3	OVERVIEW OF THE ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET	83
1.4	CURRENCY AND PRICING	85
1.5	LIMITATIONS	85
1.6	MARKETS COVERED	85
2	MARKET SEGMENTATION	89
2.1	MARKETS COVERED	89
2.2	GEOGRAPHICAL SCOPE	90
2.3	YEARS CONSIDERED FOR THE STUDY	91
2.4	DBMR TRIPOD DATA VALIDATION MODEL	92
2.5	PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	95
2.6	MULTIVARIATE MODELLING	96
2.7	PRODUCT TYPE SEGMENT LIFELINE CURVE	96
2.8	MARKET END USER COVERAGE GRID	97
2.9	DBMR MARKET POSITION GRID	98
2.10	VENDOR SHARE ANALYSIS	99
2.11	SECONDARY SOURCES	100
2.12	ASSUMPTIONS	100
3	EXECUTIVE SUMMARY	101
4	PREMIUM INSIGHTS	103
4.1	PESTAL ANALYSIS	104
4.2	PORTERS 5 FORCES	105
5	ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: REGULATIONS	106
6	MARKET OVERVIEW	114
6.1	DRIVERS	116
6.1.1	RISING PREVALENCE OF CANCER INCIDENCES	116
6.1.2	RISING TECHNOLOGICAL ADVANCEMENTS	116
6.1.3	INCREASED UNDERSTANDING OF TUMOR MICROENVIRONMENT	117
6.1.4	RISE IN PATIENT AWARENESS AND DEMAND FOR TARGETED TREATMENT	117

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.2 RESTRAINTS	118
6.2.1 INCREASING OCCURRENCE OF IMMUNE-RELATED ADVERSE EVENTS	118
6.2.2 DEVELOPING RESISTANCE TO CANCER TREATMENT	118
6.3 OPPORTUNITIES	119
6.3.1 GROWING TREND TOWARDS COMBINATION THERAPIES	119
6.3.2 RISING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND DIGITAL HEALTH TOOLS	119
6.3.3 DEVELOPMENT OF NEXT-GENERATION IMMUNOTHERAPIES	120
6.4 CHALLENGES	121
6.4.1 LACK OF STANDARDIZATION IN BIOMARKER TESTING	121
6.4.2 COMPLEXITY OF DEVELOPING AND IMPLEMENTING PERSONALIZED MEDICINE	121
7 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET , BY PRODUCT TYPE	122
7.1 OVERVIEW	123
7.2 CHECKPOINT INHIBITORS	126
7.2.1 PROGRAMMED DEATH 1 (PD-1) & PROGRAMMED DEATH LIGAND 1 (PD-L1)	127
7.2.2 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4)	127
7.3 MONOCLONAL ANTIBODIES	128
7.3.1 NAKED MONOCLONAL ANTIBODIES	129
7.3.2 CONJUGATED MONOCLONAL ANTIBODIES	129
7.3.3 BISPECIFIC MONOCLONAL ANTIBODIES	129
7.4 VACCINES	130
7.4.1 PROPHYLACTIC VACCINES	131
7.4.2 THERAPEUTIC VACCINES	131
7.5 CELL THERAPIES	131
7.5.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY	132
7.5.2 T CELL THERAPY	132
7.6 IMMUNOMODULATORS	132
7.6.1 INTERFERONS	133
7.6.2 INTERLEUKINS	133
7.6.3 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR	133
7.7 ONCOLYTIC VIRUS	134
8 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET , BY END USER	135
8.1 OVERVIEW	136
8.2 HOSPITALS	139
8.3 ONCOLOGY CLINICS	140
8.4 HOMECARE	140
8.5 OTHERS	141
9 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL	142
9.1 OVERVIEW	143
9.2 DIRECT TENDERS	146
9.3 RETAIL SALES	147
9.4 PHARMACIES	147
9.4.1 HOSPITAL	148
9.4.2 RETAIL	148
9.4.3 ONLINE	148
10 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, BY FORM	149
10.1 OVERVIEW	150
10.2 INTRAVENOUS (IV)	153

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.3 INTRAMUSCULAR 154
- 10.4 ORAL 154
- 11 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, BY APPLICATION 155
 - 11.1 OVERVIEW 156
 - 11.2 LUNG CANCER 159
 - 11.2.1 CHECKPOINT INHIBITORS 160
 - 11.2.2 MONOCLONAL ANTIBODIES 160
 - 11.2.3 CELL THERAPIES 160
 - 11.2.4 IMMUNOMODULATORS 160
 - 11.3 BREAST CANCER 161
 - 11.3.1 CHECKPOINT INHIBITORS 161
 - 11.3.2 MONOCLONAL ANTIBODIES 161
 - 11.3.3 CELL THERAPIES 162
 - 11.3.4 IMMUNOMODULATORS 162
 - 11.4 MELANOMA 162
 - 11.4.1 CHECKPOINT INHIBITORS 163
 - 11.4.2 MONOCLONAL ANTIBODIES 163
 - 11.4.3 CELL THERAPIES 163
 - 11.4.4 IMMUNOMODULATORS 163
 - 11.4.5 ONCOLYTIC VIRUS 163
 - 11.5 MULTIPLE MYELOMA 164
 - 11.5.1 CHECKPOINT INHIBITORS 164
 - 11.5.2 MONOCLONAL ANTIBODIES 164
 - 11.5.3 CELL THERAPIES 164
 - 11.5.4 IMMUNOMODULATORS 165
 - 11.6 PROSTATE CANCER 165
 - 11.6.1 CHECKPOINT INHIBITORS 165
 - 11.6.2 MONOCLONAL ANTIBODIES 166
 - 11.6.3 CELL THERAPIES 166
 - 11.6.4 IMMUNOMODULATORS 166
 - 11.6.5 VACCINES 166
 - 11.7 OVARIAN CANCER 166
 - 11.7.1 CHECKPOINT INHIBITORS 167
 - 11.7.2 MONOCLONAL ANTIBODIES 167
 - 11.7.3 CELL THERAPIES 167
 - 11.7.4 IMMUNOMODULATORS 167
 - 11.8 CERVICAL CANCER 168
 - 11.8.1 CHECKPOINT INHIBITORS 168
 - 11.8.2 MONOCLONAL ANTIBODIES 168
 - 11.8.3 VACCINES 169
 - 11.8.4 CELL THERAPIES 169
 - 11.8.5 IMMUNOMODULATORS 169
 - 11.9 STOMACH CANCER 169
 - 11.9.1 CHECKPOINT INHIBITORS 170
 - 11.9.2 MONOCLONAL ANTIBODIES 170
 - 11.9.3 CELL THERAPIES 170
 - 11.9.4 IMMUNOMODULATORS 170

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.10 COLORECTAL CANCER 170
 - 11.10.1 CHECKPOINT INHIBITORS 171
 - 11.10.2 MONOCLONAL ANTIBODIES 171
 - 11.10.3 CELL THERAPIES 171
 - 11.10.4 IMMUNOMODULATORS 171
- 11.11 HEAD AND NECK CANCER 172
 - 11.11.1 CHECKPOINT INHIBITORS 172
 - 11.11.2 MONOCLONAL ANTIBODIES 172
 - 11.11.3 CELL THERAPIES 172
 - 11.11.4 IMMUNOMODULATORS 173
- 11.12 OTHERS 173
 - 11.12.1 CHECKPOINT INHIBITORS 173
 - 11.12.2 MONOCLONAL ANTIBODIES 173
 - 11.12.3 VACCINES 174
 - 11.12.4 CELL THERAPIES 174
 - 11.12.5 IMMUNOMODULATORS 174
- 12 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, BY REGION 175
 - 12.1 ASIA-PACIFIC 177
 - 12.1.1 CHINA 186
 - 12.1.2 JAPAN 194
 - 12.1.3 INDIA 202
 - 12.1.4 SOUTH KOREA 210
 - 12.1.5 AUSTRALIA 218
 - 12.1.6 SINGAPORE 227
 - 12.1.7 THAILAND 236
 - 12.1.8 INDONESIA 244
 - 12.1.9 PHILIPPINES 253
 - 12.1.10 MALAYSIA 262
 - 12.1.11 VIETNAM 270
 - 12.1.12 REST OF ASIA-PACIFIC 278
- 13 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, COMPANY LANDSCAPE 279
 - 13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 279
- 14 SWOT ANALYSIS 280
- 15 COMPANY PROFILES 281
 - 15.1 MERCK & CO., INC. 281
 - 15.1.1 COMPANY SNAPSHOT 281
 - 15.1.2 REVENUE ANALYSIS 281
 - 15.1.3 COMPANY SHARE ANALYSIS 282
 - 15.1.4 PRODUCT PORTFOLIO 282
 - 15.1.5 RECENT DEVELOPMENTS 282
 - 15.2 F. HOFFMANN-LA ROCHE LTD 283
 - 15.2.1 COMPANY SNAPSHOT 283
 - 15.2.2 REVENUE ANALYSIS 283
 - 15.2.3 COMPANY SHARE ANALYSIS 284
 - 15.2.4 PRODUCT PORTFOLIO 284
 - 15.2.5 RECENT DEVELOPMENTS 284
 - 15.3 BRISTOL-MYERS SQUIBB COMPANY 286

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.3.1 COMPANY SNAPSHOT 286
- 15.3.2 REVENUE ANALYSIS 286
- 15.3.3 COMPANY SHARE ANALYSIS 287
- 15.3.4 PRODUCT PORTFOLIO 287
- 15.3.5 RECENT DEVELOPMENTS 288
- 15.4 JANSSEN ASIA PACIFIC SERVICES, LLC 289
- 15.4.1 COMPANY SNAPSHOT 289
- 15.4.2 REVENUE ANALYSIS 289
- 15.4.3 COMPANY SHARE ANALYSIS 290
- 15.4.4 PRODUCT PORTFOLIO 290
- 15.4.5 RECENT DEVELOPMENTS 291
- 15.5 ASTRAZENECA 292
- 15.5.1 COMPANY SNAPSHOT 292
- 15.5.2 REVENUE ANALYSIS 292
- 15.5.3 COMPANY SHARE ANALYSIS 293
- 15.5.4 PRODUCT PORTFOLIO 293
- 15.5.5 RECENT DEVELOPMENTS 294
- 15.6 ABBVIE INC. 295
- 15.6.1 COMPANY SNAPSHOT 295
- 15.6.2 PIPELINE PORTFOLIO 295
- 15.6.3 RECENT DEVELOPMENTS 295
- 15.7 AMGEN INC. 296
- 15.7.1 COMPANY SNAPSHOT 296
- 15.7.2 REVENUE ANALYSIS 297
- 15.7.3 PIPELINE PORTFOLIO 297
- 15.7.4 PRODUCT PORTFOLIO 298
- 15.7.5 RECENT DEVELOPMENTS 298
- 15.8 ATARA BIOTHERAPEUTICS, INC. 299
- 15.8.1 COMPANY SNAPSHOT 299
- 15.8.2 PIPELINE PORTFOLIO 299
- 15.8.3 RECENT DEVELOPMENTS 299
- 15.9 BAYER AG 300
- 15.9.1 COMPANY SNAPSHOT 300
- 15.9.2 PIPELINE PORTFOLIO 300
- 15.9.3 RECENT DEVELOPMENTS 300
- 15.10 CELLDEX THERAPEUTICS. 302
- 15.10.1 COMPANY SNAPSHOT 302
- 15.10.2 PIPELINE PORTFOLIO 302
- 15.10.3 RECENT DEVELOPMENTS 302
- 15.11 CELLECTIS 303
- 15.11.1 COMPANY SNAPSHOT 303
- 15.11.2 PIPELINE PORTFOLIO 303
- 15.11.3 RECENT DEVELOPMENTS 303
- 15.12 GILEAD SCIENCES, INC. 304
- 15.12.1 COMPANY SNAPSHOT 304
- 15.12.2 REVENUE ANALYSIS 304
- 15.12.3 PRODUCT PORTFOLIO 305

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.12.4 RECENT DEVELOPMENTS	305
15.13 GSK PLC.	306
15.13.1 COMPANY SNAPSHOT	306
15.13.2 REVENUE ANALYSIS	306
15.13.3 PRODUCT PORTFOLIO	307
15.13.4 RECENT DEVELOPMENTS	307
15.14 INCYTE.	308
15.14.1 COMPANY SNAPSHOT	308
15.14.2 REVENUE ANALYSIS	308
15.14.3 PRODUCT PORTFOLIO	309
15.14.4 RECENT DEVELOPMENTS	309
15.15 LILLY.	310
15.15.1 COMPANY SNAPSHOT	310
15.15.2 REVENUE ANALYSIS	311
15.15.3 PRODUCT PORTFOLIO	311
15.15.4 RECENT DEVELOPMENTS	312
15.16 NOVARTIS AG	313
15.16.1 COMPANY SNAPSHOT	313
15.16.2 REVENUE ANALYSIS	313
15.16.3 PIPELINE PORTFOLIO	314
15.16.4 PRODUCT PORTFOLIO	314
15.16.5 RECENT DEVELOPMENTS	314
15.17 PFIZER INC.	315
15.17.1 COMPANY SNAPSHOT	315
15.17.2 REVENUE ANALYSIS	315
15.17.3 PRODUCT PORTFOLIO	316
15.17.4 RECENT DEVELOPMENTS	316
16 QUESTIONNAIRE	317
17 RELATED REPORTS	321
?	

APAC Cancer Immunotherapy Market - Industry Trends and Forecast to 2032

Market Report | 2023-12-01 | 321 pages | Data Bridge Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scottss-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scottss-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-30"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scottss-international.com

www.scottss-international.com